Phio Pharmaceuticals (PHIO) Current Assets (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Current Assets came in at $17.4 million in Q1 2026, up 29.52% YoY from $13.4 million in Q1 2025, and down 18.97% on a QoQ basis from $21.5 million in Q4 2025.
Phio Pharmaceuticals (PHIO) Current Assets (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Current Assets data on file, last reported at $17.4 million in Q1 2026.
- Quarterly Current Assets rose 29.52% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.4 million (up 29.52% YoY) and the FY2025 annual result came in at $21.5 million, up 274.41% from the prior year.
- Current Assets slipped to $17.4 million in Q1 2026, from $21.5 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $21.7 million in Q1 2022 to a low of $5.3 million in Q2 2024.
- A 5-year average of $12.2 million and a median of $11.5 million in 2025 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets slumped 56.6% — and 2025, when it jumped 274.41%.
- Tracing PHIO's Current Assets over 5 years: stood at $12.4 million in 2022, then dropped by 25.1% to $9.3 million in 2023, then plunged by 38.47% to $5.7 million in 2024, then jumped by 274.41% to $21.5 million in 2025, then retreated by 18.97% to $17.4 million in 2026.
- The last three Current Assets figures came in at $17.4 million (Q1 2026), $21.5 million (Q4 2025), and $11.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | 14.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.30 Mn |
| Mar 31, 2026 | 17.40 Mn |
| Dec 31, 2025 | 21.48 Mn |
| Sep 30, 2025 | 11.49 Mn |
| Jun 30, 2025 | 11.29 Mn |
| Mar 31, 2025 | 13.44 Mn |
| Dec 31, 2024 | 5.74 Mn |
| Sep 30, 2024 | 5.86 Mn |
| Jun 30, 2024 | 5.29 Mn |
| Mar 31, 2024 | 6.85 Mn |
| Dec 31, 2023 | 9.32 Mn |
| Sep 30, 2023 | 9.33 Mn |
| Jun 30, 2023 | 12.04 Mn |
| Mar 31, 2023 | 9.40 Mn |
| Dec 31, 2022 | 12.45 Mn |
| Sep 30, 2022 | 15.38 Mn |
| Jun 30, 2022 | 19.69 Mn |
| Mar 31, 2022 | 21.67 Mn |
| Dec 31, 2021 | 24.73 Mn |
| Sep 30, 2021 | 27.45 Mn |